



# Standard Treatment Workflow (STW) for the Management of

# PAEDIATRIC ABDOMINAL TUBERCULOSIS

# WHEN TO SUSPECT?

- One or more of following
  - > Recurrent/chronic abdominal pain in presence of red flag signs
  - Abdominal distension/mass
  - Altered bowel habits
- Constitutional symptoms like Presence of Fever >2 weeks, Anorexia, Unexplained weight loss or no weight gain in last 3 months despite adequate nutrition may be present
- · History of contact with TB patient may also be present



# ICD-10-A18.31

#### **PERITONEAL TB**

CLINICAL FEATURES SPECIFIC TO TYPE OF ABDOMINAL TB

- Abdominal pain, distension
- Fever
- Weight loss

#### **NODAL TB**

- Pain abdomen
- Fever
- Palpable abdominal lump

### **INTESTINAL TB**

- Recurrent intestinal colic
- Altered bowel habits
- Chronic diarrhoea
- Partial/complete intestinal obstruction
- Weight loss, anorexia
- Palpable abdominal lump
- Lower gastrointestinal bleeding

#### VISCERAL TB (LIVER, **SPLEEN, PANCREAS)**

- Abdominal pain
- Fever
- Jaundice
- Weight loss
- Anorexia
- Hepatomegaly Splenomegaly
- Hepatic abscess
- Palpable
- abdominal lump
- Abnormal LFTs

#### **EXAMINATION FINDINGS**

- Anthropometry
- General physical & systemic examination
- Look for peripheral LAP, ascites, hepatosplenomegaly, doughy feel of abdomen, palpable abdominal lump, visible peristalsis or a moving mass - "gola" formation due to partially obstructed dilated bowel loop

#### **RED FLAGS**

- Pain abdomen waking child from sleep
- Chronic, severe, or nocturnal diarrhea
- Presence of constitutional symptoms like fever, anorexia, weight loss, etc. Localized distension or mass

# **INVESTIGATIONS**

#### ESSENTIAL

Ultrasound abdomen

#### **SUGGESTIVE FINDINGS**

- Abdominal LN: measuring >15 mm in short axis, conglomerate and/or central necrosis
- Omental/mesenteric thickening >15 mm with increased echogenicity

• sputum/GA/IS (If CXR abnormal) for NAAT, TB culture

Ascitic fluid (If present) for cytology, protein & albumin

Peripheral LN-FNA (If size >2 cm) for cytology, NAAT, TB

 Ileocaecal wall thickening

· Chest X Ray

### **NON SPECIFIC FINDINGS**

- Intraabdominal fluid (free or loculated) or Inter-loop ascites
- Ascitic fluid with multiple septations
- Abdominal LAP with SAD <15 mm in absence of red flag signs

### **Ascites**

### **Essential**

- If exudative ascites, ascitic fluid for NAAT, TB culture
- No role of ADA

# **Enlarged Abdominal mass**

#### Desirable

 USG guided Abdominal mass-FNA for cytology, NAAT, TB culture

#### **Optional**

 USG/CT guided core biopsy of LN for histology, NAAT, TB culture

# **Intestinal involvement**

#### Desirable

- CECT Abdomen/CT enterography
- USG guided Abdominal Mass -FNA for cytology, NAAT, culture

# **Optional**

- Ileocolonoscopy, tissue biopsy (HPE, NAAT)
- Laparoscopy, tissue biopsy for HPE, NAAT

## DIAGNOSTIC ALGORITHM

# If abdominal TB suspected

Look for peripheral nodes, get CXR and Abdominal USG

**USG** normal **USG** suggestive of TB Evaluate for other causes/ Peripheral nodes + No peripheral nodes CXR Normal **CXR** abnormal Refer to higher centre FNA for NAAT/TB Sputum/GA/IS for NAAT/TB Lymphadenopathy or Ileocecal TB\* **Ascites** culture/Cytopathology culture abdominal mass Ascitic fluid aspiration -CECT Abdomen/CT FNA for NAAT/TB Positive Negative\* Negative\* **Positive** Cytology, protein, sugar culture/Cytopathology enterography# where feasible If Exudative with lymphocytic predominance, Start treatment Start treatment ascitic fluid for NAAT/TB culture Positive **Positive** \*Consider USG guided FNA from abdominal nodes/ refer to higher centre if not available or feasible

# **TREATMENT**

# Start treatment & follow-up as per NTEP

#Consider CECT Abdomen/CT enterography if Isolated ileocaecal thickening or LN sampling not

ATT for 6 months (2HRZE + 4HRE)

feasible/Refer to higher centre if not available

- Pyridoxine supplementation- 10 mg/day
- Steroids- Routinely not recommended (SAIO)
- Supportive treatment- Management of SAM/Malnutrition as per national guidelines
- Surgical treatment:
- Acute intestinal obstruction, Bowel perforation
- > Persistence of obstructive symptoms despite conservative management & ATT
- **DO NOT** start Empirical ATT with isolated:
- > Recurrent/Chronic abdominal pain without red flag signs
- > Chronic diarrhoea without proper evaluation
- Failure to gain weight

ATT- Antitubercular treatment

**DR-TB-** Drug Resistant tuberculosis

CXR- Chest X-Ray

**CECT- Contrast Enhanced Computed Tomography** CT- Computed Tomography

E- Ethambutol

FNA- Fine Needle Aspiration **GA-** Gastric Aspirate

H- Isoniazid

**HPE-** Histopathological Examination **IBD-Inflammatory Bowel Disease** 

### MANAGEMENT MONITORING

### Assessment of response to treatment:

Start treatment

- > Clinical follow up every month during treatment & after that every 3 months
- > Radiologically by USG At the end of treatment or if worsening or non response to treatment
- Microbiological If worsening or non response to treatment
- Pointers towards DR TB investigation:
- > Non response to treatment or Worsening or deterioration of constitutional symptoms after initial improvement. Rule out Crohn's disease OR Inflammatory Bowel Disease
- Obstructive symptoms may persist or worsen despite treatment with appropriate ATT
- **Monitor for**
- Adherence to treatment (ATT)
- Adverse drug reactions- ATT induced

# WHEN TO REFER?

- Diagnosis is uncertain & additional investigations are required
- Acute intestinal obstruction or bowel perforation
- · DR TB

Start treatment

- No response to appropriate treatment
- Oral drug (ATT) intolerance/cannot be given

### ABBREVIATIONS

- IS- Induced Sputum
  - LAP- Lymphadenopathy LN- Lymph Node
  - MGIT- Mycobacteria Growth Indicator Tube
  - NAAT- Nucleic Acid Amplification Test
- SAD- Sagittal Abdominal Diameter
- SAIO- Sub Acute Intestinal Obstruction SAM- Severe Acute Malnutrition
- USG- Ultrasonography Z- Pyrazinamide

- 1. National TB Elimination Programme, Central TB Division. Training Modules for Programme Managers & Medical Officers. Ministry of Health & Family Welfare, Government of India. https://tbcindia.gov.in/index1.php?lang=1&level=1&sublinkid=5465&lid=3540 Last access on 10 March, 2022.
- 2. Guidelines for programmatic management of drug resistant tuberculosis in India March 2021. National TB Elimination Programme, Central TB Division, Ministry of Health & Family Welfare, Government of India accessed at https://tbcindia.gov.in/showfile.php?lid=3590 Last access on 10 March, 2022. This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are

based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit our web portal (stw.icmr.org.in) for more information. © Indian Council of Medical Research and Department of Health Research, Ministry of Health & Family Welfare, Government of India.